{"product_id":"sarepta-pestle-analysis","title":"Sarepta Therapeutics PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain a competitive edge with our concise PESTLE analysis of Sarepta Therapeutics, revealing regulatory, economic, and technological pressures shaping its pipeline and valuation. Ideal for investors and strategists, it highlights risks and growth levers. Purchase the full report to access deep, actionable insights and editable tools.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrphan drug policy stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrphan Drug Act incentives—notably 7 years of market exclusivity and transferable rare-disease PRVs that have historically sold for over $100 million—underpin pricing and development economics for DMD therapies like those from Sarepta. Periodic bipartisan scrutiny and bills proposing limits to exclusivity or tax benefits have increased since 2020, so monitoring proposed amendments is critical as changes could shift pipeline prioritization and ROI assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA stance on gene therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFDA leadership sets the bar for accelerated vs traditional approvals, with gene therapy guidances updated in 2020–2022 shaping acceptable endpoints, durability evidence, and heavier post‑marketing commitments. For DMD (prevalence ~1:3,500–5,000 male births) regulators increasingly demand functional outcomes over surrogate biomarkers. High‑profile safety events (eg, Zolgensma hepatic monitoring) have prompted tighter requirements and political scrutiny that can slow approvals and add costly REMS\/post‑market studies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. reimbursement politics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFederal and state debates over high-cost gene therapies shape Medicare and Medicaid coverage, with Medicaid covering over 70 million Americans and Medicare negotiation powers from the Inflation Reduction Act (negotiations begin 2026) increasing pressure on pricing. CMS and CMMI pilots for outcomes-based contracts exist and could expand with political backing. Budget constraints push stricter utilization management and prior authorization. Strong rare-disease advocacy—about 30 million Americans affected—can sway policy accommodations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical supply chain risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTrade tensions and 2023 US export controls on select biotechnology items constrain access to enzymes, plasmids and viral vector components, while sanctions and Russia\/Ukraine-related logistics disruptions have delayed GMP material shipments and extended lead times for biologics suppliers. Government initiatives such as the US National Biotechnology and Biomanufacturing Initiative (launched 2022) and increased BARDA\/public funding aim to onshore capacity and mitigate risk. Diversification into regional suppliers and partnerships with public-private manufacturing hubs can shorten timelines and reduce single‑source exposure for Sarepta's gene therapy supply chain.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExport controls 2023: limits on biotech items affecting vector inputs\u003c\/li\u003e\n\u003cli\u003eSanctions\/logistics: measurable shipment delays for GMP materials since 2022\u003c\/li\u003e\n\u003cli\u003ePolicy mitigation: US biomanufacturing initiative (2022) supports onshoring\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal health diplomacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlobal health diplomacy shapes Sarepta's approvals and market access as international alignment on advanced therapies affects timelines; EMA-MHRA-PMDA harmonization and the EU HTA Regulation (applicable Jan 2025) can accelerate launches. Political will for rare-disease coverage varies with budgets—WHO estimates ~300 million affected; OECD average health spend ~9.6% GDP (US ~17.8% in 2022). Cross-border HTA participation shifts pricing narratives.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory harmonization: EMA\/MHRA\/PMDA\u003c\/li\u003e\n\u003cli\u003eEU HTA Reg effective Jan 2025\u003c\/li\u003e\n\u003cli\u003eRare diseases: ~300 million people (WHO)\u003c\/li\u003e\n\u003cli\u003eBudget pressure: OECD health spend ~9.6% GDP, US ~17.8% (2022)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrphan exclusivity, PRVs and 2026 Medicare price talks reshape DMD economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrphan Drug Act 7-year exclusivity and transferable PRVs (\u0026gt; $100M historically) underpin DMD economics; legislative proposals since 2020 could alter incentives. Medicare negotiation under IRA begins 2026 and Medicaid covers \u0026gt;70M, pressuring high-cost gene therapies. EU HTA effective Jan 2025 and global harmonization affect launch timing; WHO estimates ~300M with rare diseases.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan exclusivity\u003c\/td\u003e\n\u003ctd\u003e7 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePRV sale price\u003c\/td\u003e\n\u003ctd\u003e\u0026gt; $100M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicaid enrollees\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare negotiation\u003c\/td\u003e\n\u003ctd\u003eStarts 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU HTA\u003c\/td\u003e\n\u003ctd\u003eEffective Jan 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare disease pop\u003c\/td\u003e\n\u003ctd\u003e~300M (WHO)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Sarepta Therapeutics across Political, Economic, Social, Technological, Environmental, and Legal dimensions, highlighting implications for rare-disease drug development and commercialization. Every section is data-backed, forward-looking, and tailored to support executives, investors, and strategists in risk mitigation and opportunity capture.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eVisually segmented PESTLE summary of Sarepta Therapeutics that relieves briefing pain points by enabling quick interpretation at a glance, easy insertion into presentations, and streamlined alignment across teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-cost therapy affordability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOne-time gene therapies like Sarepta's elevidys carry list prices in the multi-million dollar range (elevidys launched ~$3.2M), triggering payer budget-impact tests and caps on enrollments. Outcomes-based agreements and amortization installments have increased uptake flexibility. DMD value assessments weigh measurable functional gains against caregiver cost offsets (often tens of thousands USD\/year) within ICER-style thresholds of ~$100k–$150k\/QALY, while macro fiscal pressures limit coverage generosity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital market conditions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInterest rates and risk appetite drive biotech financing costs and runway, with the US federal funds target at 5.25–5.50% (July 2025) increasing cost of capital. Market volatility erodes partnering leverage and raises the likelihood of equity dilution. Strong clinical readouts can decouple Sarepta from indices but timing is critical. Strategic alliances can supplement funding during tight cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing scale economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFor Sarepta, AAV\/RNA yield improvements—industry-wide gains of up to 40%—can materially lower COGS and boost margins; single-use systems cut upfront capex by roughly 30% but raise consumables spend, tightening gross margins over time. 2024 capacity crunches pushed CDMO slot premiums near 25%, forcing premium pricing or outsourcing. Scaling beyond DMD can halve per-patient manufacturing costs as volumes rise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer mix and HTA outcomes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIn the U.S., Sarepta’s commercial versus Medicaid mix materially affects net price realization given Medicaid enrollment of ~86 million (2024) and a statutory brand rebate floor of 23.1%; ex-U.S., HTA decisions force price–volume trade-offs where ICER thresholds of roughly $100,000–$150,000\/QALY prioritize long-term durability evidence; rebates and managed entry agreements compress near-term cash flows.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedicaid enrollment ~86M (2024)\u003c\/li\u003e\n\u003cli\u003eStatutory Medicaid rebate floor 23.1%\u003c\/li\u003e\n\u003cli\u003eICER benchmarks ~$100k–$150k\/QALY\u003c\/li\u003e\n\u003cli\u003eRebates\/MEAs reduce near-term cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFX and geographic expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCurrency swings affect ex-U.S. revenues and imported input costs, creating margin volatility for Sarepta. Sequencing launches into high-value markets like EU, UK and Japan optimizes ROI by prioritizing reimbursement and pricing. Localization of supply reduces FX exposure but raises fixed manufacturing costs; hedging policies stabilize trial budgets and COGS planning.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFX exposure → revenue and input-cost volatility\u003c\/li\u003e\n\u003cli\u003eMarket sequencing → higher ROI via reimbursement\u003c\/li\u003e\n\u003cli\u003eLocal supply → lower FX risk, higher fixed costs\u003c\/li\u003e\n\u003cli\u003eHedging → more predictable trial and COGS planning\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrphan exclusivity, PRVs and 2026 Medicare price talks reshape DMD economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSarepta faces multi-million list prices (elevidys ~$3.2M) triggering payer caps and outcomes agreements, while ICER-style thresholds (~$100k–$150k\/QALY) and macro fiscal pressure limit coverage generosity. Higher rates (fed funds 5.25–5.50% July 2025) raise capital costs and dilution risk; manufacturing gains (AAV yield +40%) and CDMO premiums (~25%) drive margins and timing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eElevidys list price\u003c\/td\u003e\n\u003ctd\u003e~$3.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicaid enrollment (2024)\u003c\/td\u003e\n\u003ctd\u003e~86M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicaid rebate\u003c\/td\u003e\n\u003ctd\u003e23.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eICER threshold\u003c\/td\u003e\n\u003ctd\u003e$100k–$150k\/QALY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds (Jul 2025)\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAAV yield gains\u003c\/td\u003e\n\u003ctd\u003eup to +40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO slot premium (2024)\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eSarepta Therapeutics PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThis Sarepta Therapeutics PESTLE Analysis provides a concise review of political, economic, social, technological, legal, and environmental factors affecting the company; the preview shown here is the exact document you’ll receive after purchase—fully formatted and ready to use. Use it immediately for strategic or investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55675477590393,"sku":"sarepta-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/sarepta-pestle-analysis.png?v=1755809366","url":"https:\/\/portersfiveforce.com\/products\/sarepta-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}